{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:12:25Z","timestamp":1772748745109,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,8,6]],"date-time":"2012-08-06T00:00:00Z","timestamp":1344211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Purpose:\u00a0<\/jats:bold> To evaluate the efficacy and safety profile of eslicarbazepine acetate (ESL) added to stable antiepileptic therapy in adults with partial\u2010onset seizures.<\/jats:p><jats:p><jats:bold>Methods:\u00a0<\/jats:bold> Data from 1,049 patients enrolled from 125 centers, in 23 countries, in three phase III double\u2010blind, randomized, placebo\u2010controlled studies were pooled and analyzed. Following a 2\u2010week titration period, ESL was administered at 400\u2003mg, 800\u2003mg, and 1,200\u2003mg once\u2010daily doses for 12\u2003weeks.<\/jats:p><jats:p><jats:bold>Key Findings:\u00a0<\/jats:bold> Seizure frequency was significantly reduced with ESL 800\u2003mg (p\u2003&lt;\u20030.0001) and 1,200\u2003mg (p\u2003&lt;\u20030.0001) compared to placebo. Median relative reduction in seizure frequency was, respectively, 35% and 39% (placebo 15%) and responder rate was 36% and 44% (placebo 22%). ESL was more efficacious than placebo regardless of gender, geographic region, epilepsy duration, age at time of diagnosis, seizure type, and number and type of concomitant antiepileptic drugs (AEDs). Incidence of adverse events (AEs) and AEs leading to discontinuation were dose dependent. AEs occurred mainly during the first weeks of treatment, with no difference between groups after 6\u2003weeks. Most common AEs (&gt;10% patients) were dizziness, somnolence, and headache. The incidence of AEs in ESL groups compared to placebo was generally consistent among different subpopulations.<\/jats:p><jats:p><jats:bold>Significance:\u00a0<\/jats:bold> Once\u2010daily ESL 800 mg and 1,200\u2003mg showed consistent results across all efficacy and safety end points. Results were independent of study population characteristics and type and number of concomitant AEDs.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2012.03605.x","type":"journal-article","created":{"date-parts":[[2012,8,6]],"date-time":"2012-08-06T14:41:48Z","timestamp":1344264108000},"page":"98-107","source":"Crossref","is-referenced-by-count":74,"title":["Efficacy and safety of eslicarbazepine acetate as add\u2010on treatment in patients with focal\u2010onset seizures: Integrated analysis of pooled data from double\u2010blind phase III clinical studies"],"prefix":"10.1111","volume":"54","author":[{"given":"Ant\u00f3nio","family":"Gil\u2010Nagel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Elger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elinor","family":"Ben\u2010Menachem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hal\u00e1sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Lopes\u2010Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto A.","family":"Gabbai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcio","family":"Soares\u2010da\u2010Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,8,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008319706"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0414-1"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444316667.ch38"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01233.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014814924965"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1499-1654.2000.001597.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm980627g"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.01.014"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03519.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.43600.x"},{"key":"e_1_2_7_12_1","first-page":"258","article-title":"Eslicarbazepine and R\u2010licarbazepine do not have effects on ion transmission through alpha1, alpha2, alpha3 and alpha5 GABA channels","volume":"52","author":"Bonifacio MJ","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_13_1","first-page":"260","article-title":"The effects of eslicarbazepine, R\u2010licarbazepine, oxcarbazepine and carbamazepine on ion transmission Cav3.2 channels","volume":"52","author":"Brady K","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7528.1317"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)01007-8"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00984.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01946.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.549"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.06304.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01218.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00231-5"},{"key":"e_1_2_7_22_1","first-page":"257","article-title":"Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage\u2010gated sodium channels","volume":"52","author":"Hebeisen S","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46119"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444316667.ch9"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2011.05.013"},{"key":"e_1_2_7_26_1","first-page":"118","article-title":"Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the maximal electroconvulsive test in the mice","volume":"52","author":"Pires N","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02175.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.009340"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444316667.ch36"},{"key":"e_1_2_7_30_1","first-page":"258","article-title":"The effects of eslicarbazepine, R\u2010licarbazepine and carbamazepine on ion transmission through Kv7.2 channels","volume":"52","author":"Soares\u2010da\u2010Silva P","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_31_1","first-page":"118","article-title":"The effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the 6\u2010Hz psychomotor seizure model in the mice","volume":"52","author":"Torrao L","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444316667.ch7"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2012.03605.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2012.03605.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:17:53Z","timestamp":1698664673000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2012.03605.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1528-1167.2012.03605.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03605.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,6]]}}}